Published on
15:00 GMT
Allogenic T Regulatory Cell Product CK0801 Granted FDA Orphan Drug Designation for Aplastic Anemia Treatment
The FDA has granted orphan drug designation (ODD) to CK0801, an allogeneic T regulatory (Treg) cell therapy developed by Cellenkos Inc for the treatment of aplastic anemia.1 The ODD allows for expedited development of treatments for rare diseases;2 with an …
Source:
Pharmacy Times
-
Neutral
